Continuing Medical Education
Potential Risks for the Off-Label Use of SSRIs in Premature Ejaculation (CME)
Jay Lee MD,
Jay Lee MD
Southern Alberta Institute of Urology, Calgary, AB, Canada
Search for more papers by this authorJay Lee MD,
Jay Lee MD
Southern Alberta Institute of Urology, Calgary, AB, Canada
Search for more papers by this authorFirst published: 02 August 2010
Jay Lee, MD, Southern Alberta Institute of Urology, Suite 6610, 7007—14 Street SW, Calgary, Alberta, Canada T2V 1P9. Tel: 403-943-8985; Fax: 403-943-8984; E-mail: [email protected]
References
- 1 Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B. Effect of SSRI antidepressants on ejaculation: A double blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol 1998; 18: 274–81.
- 2 Sharlip I. Diagnosis and treatment of premature ejaculation: The physician perspective. J Sex Med 2005; 2(suppl): 103–9.
- 3 Goodman RE. An assessment of clomipramine (Anafranil) in the treatment of premature ejaculation. J Int Med Res 1980; 8(3 suppl): 53–9.
- 4 Montague DK, Jarow J, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, Nehra A, Sharlip ID. AUA Erectile Dysfunction Guideline Update Panel. AUA guideline on the pharmacologic management of premature ejaculation. J Urol 2004; 172: 290–4.
- 5 Kim SC, Seo KK. Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: A double-blind, placebo controlled study. J Urol 1998; 159: 425–7.
- 6 Salonia A, Maga T, Columbo R, Scattoni V, Briganti A, Cestari A, Guazzoni G, Rigati P, Montorsi F. A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation. J Urol 2002; 168: 2486–9.
- 7 Abdel-Hamid IA, El Naggar EA, El Gilany AH. Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation. Int J Impot Res 2001; 13: 41–5.
- 8 Haensel SM, Klem T, Hop WJC, Slob AK. Fluoxetine and premature ejaculation. J Clin Psychopharmacol 1998; 18: 1–6.
- 9 Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial. Biol Psychiatry 1998; 44: 77–87.
- 10 Hetrick S, Merry S, McKenzie J, Sindahl P, Proctor M. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database Syst Rev 2007; 18:CD004851.
- 11 Wallerstedt SM, Gleerup H, Sundstrom A, Stigendal L, Ny L. Risk of clinically relevant bleeding in warfarin-treated patients—Influence of SSRI treatment. Pharmacoepidemiol Drug Saf 2009; 18: 412–6.
- 12 Mort JR, Aparasu RR, Baer RK. Interaction between selective serotonin reuptake inhibitors and nonsteroidal anti-inflammatory durgs: Review of the literature. Pharmacotherapy 2006; 26: 1307–13.
- 13 Jackson WK, Roose SP, Glassman AH. Cardiovascular toxicity and tricyclic antidepressants. Biomed Pharmacother 1987; 41: 377–82.
- 14 Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: Prevalence and predictors. JAMA 1999; 281: 537–44.
